{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:34:24Z","timestamp":1790213664756,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010481","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000}}],"reference-count":72,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010481.pub2","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T21:19:52Z","timestamp":1448313592000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function"],"prefix":"10.1002","volume":"2015","author":[{"given":"Juan Pablo","family":"Botero Aguirre","sequence":"first","affiliation":[{"name":"Hospital Pablo Tobon Uribe; Calle 78B #69-240 Medellin Antioquia Colombia 05001000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra Maria","family":"Restrepo Hamid","sequence":"additional","affiliation":[{"name":"Hospital Pablo Tobon Uribe; Emergency Department; Calle 78B #69-240 Medellin Angioquia Colombia 05001000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD010481.pub2-BIB0001|cit1","first-page":"662","article-title":"Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection","volume":"50","author":"Bodhe","year":"2002","journal-title":"Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0002|cit2","unstructured":"Hamill RJ Sobel JD El Sadr W Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract no:1161] Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1999 Sept 26-29; San Francisco, CA 1999"},{"issue":"2","key":"10.1002\/14651858.CD010481.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0019-509X.98933","article-title":"A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India","volume":"49","author":"Jadhav","year":"2012","journal-title":"Indian Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010481.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD010481.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"3-4","key":"10.1002\/14651858.CD010481.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1399-3062.2005.00108.x","article-title":"Low-dose amphotericin for prevention of serious fungal infection following liver transplantation","volume":"7","author":"Shah","year":"2005","journal-title":"Transplant Infectious Disease"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD010481.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","article-title":"A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study","volume":"17","author":"Thakur","year":"2001","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0015|cit13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/49.suppl_1.81","article-title":"Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"49 Suppl 1","author":"Cagnoni","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0013|cit14","first-page":"587a","article-title":"Pharmacoeconomic assessment of liposomal amphotericin B versus conventional amphotericin B deoxycholate in the empirical treatment of persistently febrile neutropenic patients [abstract no: 2268]","volume":"17","author":"Cagnoni","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010481.pub2-BIB0014|cit15","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.[Erratum appears in J Clin Oncol 2000 Aug;18(16):3064]","volume":"18","author":"Cagnoni","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010481.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0017|cit17","unstructured":"Anaissie E White M Uzun O Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized, multicenter trial [abstract no: LM2] 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);1995 Sep 17-20; San Francisco (CA) 1995 330"},{"issue":"8","key":"10.1002\/14651858.CD010481.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD010481.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD010481.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4269\/ajtmh.2006.75.1108","article-title":"Oral rehydration solution to prevent nephrotoxicity of amphotericin B","volume":"75","author":"Echevarria","year":"2006","journal-title":"American Journal of Tropical Medicine & Hygiene"},{"issue":"7286","key":"10.1002\/14651858.CD010481.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"BMJ"},{"issue":"5-6","key":"10.1002\/14651858.CD010481.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","article-title":"Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia","volume":"40","author":"Fleming","year":"2001","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0023|cit23","first-page":"S8","article-title":"Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations","volume":"14 Suppl 5","author":"Heinemann","year":"1994","journal-title":"Bone Marrow Transplantation"},{"issue":"11 Pt 2","key":"10.1002\/14651858.CD010481.pub2-BIB0024|cit24","first-page":"431","article-title":"Benefit of early switch to liposomal amphotericin B in patients with amphotericin B deoxycholate-induced nephrotoxicity versus late switch [abstract no: 5381]","volume":"106","author":"Isnard","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD010481.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1093\/ndt\/gfm394","article-title":"A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment","volume":"22","author":"Isnard","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.medmal.2007.11.016","article-title":"Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections","volume":"38","author":"Isnard","year":"2008","journal-title":"Medecine et Maladies Infectieuses"},{"issue":"2","key":"10.1002\/14651858.CD010481.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","article-title":"Effect of salt supplementation on amphotericin B nephrotoxicity","volume":"40","author":"Llanos","year":"1991","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD010481.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0272-6386(98)70046-0","article-title":"Renal effects of amphotericin B lipid complex","volume":"31","author":"Luke","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0030|cit30","unstructured":"al-Haddadin D Safety and efficacy of amphotericin B lipid complex in the treatment of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome www.clinicaltrials.gov\/ct2\/show\/NCT00002019"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0031|cit31","unstructured":"Sundar S A randomised, open-label, parallel-group, safety and efficacy study to evaluate different combination treatment regimens (co-administration), of ambisome, paromomycin and miltefosine in visceral leishmaniasis (VL) www.clinicaltrials.gov\/ct2\/show\/NCT00523965"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0032|cit32","unstructured":"Rahman R Phase III, open label, randomised, study of three short course combination regimens (ambisome\u00a9, miltefosine, paromomycin) compared with ambisome\u00a9 alone for the treatment of visceral leishmaniasis (VL) in Bangladesh www.clinicaltrials.gov\/ct2\/show\/NCT01122771"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0033|cit33","unstructured":"Romero G Multicentric efficacy and safety study of antileishmanial drugs for treatment of visceral leishmaniasis in Brazil www.clinicaltrials.gov\/ct2\/show\/NCT01310738"},{"issue":"2","key":"10.1002\/14651858.CD010481.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010481.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/00003246-199608000-00007","article-title":"Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients","volume":"24","author":"Sorkine","year":"1996","journal-title":"Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010481.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","article-title":"Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial","volume":"72","author":"Subira","year":"2004","journal-title":"European Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD010481.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"e3169","DOI":"10.1371\/journal.pntd.0003169","article-title":"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study","volume":"8","author":"Sundar","year":"2014","journal-title":"PLoS Neglected Tropical Diseases [electronic resource]"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00007890-199501150-00009","article-title":"Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study","volume":"59","author":"Tollemar","year":"1995","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0039|cit39","first-page":"1195","article-title":"Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial","volume":"27","author":"Tollemar","year":"1995","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0040|cit40","first-page":"1833","article-title":"Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies","volume":"26","author":"Tollemar","year":"1994","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010481.pub2-BIB0041|cit41","first-page":"S151","article-title":"Double-blind randomized trials with AmBisome as prophylaxis in bone marrow and liver transplant patients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD010481.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49 Suppl 1","author":"Adler-Moore","year":"2002","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD010481.pub2-BIB0044|cit44","first-page":"487-94","article-title":"Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility","volume":"14","author":"Arendrup","year":"2008","journal-title":"Clinical Microbiology\u00a0&\u00a0Infection"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tim.2014.01.001","article-title":"A neglected epidemic: fungal infections in HIV\/AIDS","volume":"22","author":"Armstrong-James","year":"2014","journal-title":"Trends in Microbiology"},{"issue":"11","key":"10.1002\/14651858.CD010481.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/11593760-000000000-00000","article-title":"Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients","volume":"31","author":"Bassetti","year":"2011","journal-title":"Clinical Drug Investigation"},{"issue":"5","key":"10.1002\/14651858.CD010481.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"686-93","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"6082","key":"10.1002\/14651858.CD010481.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1126\/science.1222236","article-title":"Tackling human fungal infections","volume":"336","author":"Brown","year":"2012","journal-title":"Science"},{"issue":"5-6","key":"10.1002\/14651858.CD010481.pub2-BIB0049|cit49","first-page":"283-5","article-title":"Cryptococcus and cryptococcosis in the twenty-first century","volume":"173","author":"Poeta","year":"2012","journal-title":"Mycopathologia"},{"issue":"10","key":"10.1002\/14651858.CD010481.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"921-3","DOI":"10.7326\/0003-4819-124-10-199605150-00011","article-title":"Lipid formulations for amphotericin B: does the emperor need new clothes?","volume":"124","author":"Graybill","year":"1996","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0052|cit52","first-page":"1519","article-title":"Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program","volume":"42","author":"Hajjeh\u00a0RA","year":"2004","journal-title":"Journal of Clinical\u00a0Microbiology"},{"issue":"7414","key":"10.1002\/14651858.CD010481.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0054|cit54","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11096-012-9654-y","article-title":"Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions","volume":"34","author":"Horwitz","year":"2012","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3201\/eid0703.017302","article-title":"Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome","volume":"7","author":"Husain\u00a0S","year":"2001","journal-title":"Emerging Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD010481.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000969.pub2","article-title":"Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia","author":"Johansen","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0058|cit58","first-page":"12-6","article-title":"What is the current and future status of conventional amphotericin B?","volume":"27 Suppl 1","author":"Kleinberg","year":"2006","journal-title":"International Journal of Antimicrobial\u00a0Agents"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn","year":"2009","journal-title":"Revista Iberoamericana de Micolog\u00eda"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0060|cit60","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD010481.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/cis290","article-title":"Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis","volume":"54","author":"Mistro","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"645-53","DOI":"10.1007\/s15010-013-0432-0","article-title":"Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project)","volume":"41","author":"Montagna","year":"2013","journal-title":"Infection"},{"issue":"6","key":"10.1002\/14651858.CD010481.pub2-BIB0064|cit64","first-page":"983","article-title":"Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia","volume":"18","author":"Noguchi","year":"2013","journal-title":"International Journal\u00a0of Clinical\u00a0Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010481.pub2-BIB0065|cit65","first-page":"415-25","article-title":"Amphotericin B: time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/molecules19011085","article-title":"Invasive fungal infections in the ICU: how to approach, how to treat","volume":"19","author":"Paramythiotou","year":"2014","journal-title":"Molecules"},{"issue":"1","key":"10.1002\/14651858.CD010481.pub2-BIB0067|cit67","first-page":"1-53","article-title":"Epidemiology of invasive mycoses in North America","volume":"36","author":"Pfaller","year":"2010","journal-title":"Critical\u00a0Reviews in\u00a0Microbiology"},{"issue":"8","key":"10.1002\/14651858.CD010481.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00365540903022824","article-title":"Nosocomial candidaemia in a Finnish tertiary care centre during 1987-2004","volume":"41","author":"Poikonen","year":"2009","journal-title":"Scandinavian Journal\u00a0of Infectious Diseases"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0069|cit69","volume-title":"Micromedex","author":"Truven Health Analytics","year":"2014"},{"key":"10.1002\/14651858.CD010481.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.3109\/1354750X.2011.587129","article-title":"Biomarkers of kidney injury","volume":"16 Suppl 1","author":"Urbschat","year":"2011","journal-title":"Biomarkers"},{"issue":"2","key":"10.1002\/14651858.CD010481.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e85214","DOI":"10.1371\/journal.pone.0085214","article-title":"Clinical analysis of cause, treatment and prognosis in acute kidney injury patients","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One [Electronic Resource]"},{"issue":"4","key":"10.1002\/14651858.CD010481.pub2-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010481","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function","author":"Botero Aguirre","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010481.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T10:47:10Z","timestamp":1696157230000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010481.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":72,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010481.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]}}}